Potent immunosuppressant (same as FK-506 and rapamycin).
Forms a complex with cyclophilin. Inhibits the activity of the calcium/calmodulin-dependent protein phosphatase 2B (PP2B; calcineurin). Prevents the dephosphorylation of nuclear factor of activated T cells (NFAT) transcription factor, leading to disruption of T cell activation.
Suppresses proliferation of cytotoxic T cells and inhibits the production of T cell-derived mediators such as interleukin-2 (IL-2).
Prevents rejection of transplanted organs.
Anti-inflammatory compound in the treatment of several inflammatory skin diseases (e.g. atopic dermatitis) and with potential anti-rheumatic activity (rheumatoid arthritis).
Antibacterial. Antifungal. Antiparasitic.
Apoptosis inhibitor. Inhibits the mitochondrial permeability transition pore (MPTP) from opening, thus inhibiting cytochrome c release.
NF-kappaB suppressor by induction of unfolded protein response (UPR).
Anti-cancer compound. Apoptosis and autophagy inducer.
Inhibits nitric oxide synthesis induced by interleukin-1alpha, lipopolysaccharides and TNF-alpha.
Storage and Stability:
Short-term Storage: +4°C
Long-term Storage: -20°C
Stable for at least 3 years after receipt when stored at -20°C.
Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Product Reference: |
Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A: D.A. Fruman, et al.; PNAS 89, 3686 (1992)
Cyclosporin A, FK506 and rapamycin: more than just immunosuppression: J. Kunz & M.N. Hall; TIBS 18, 334 (1993)
Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology: B.E. Bierer, et al.; Curr. Opin. Immunol. 5, 763 (1993)
Immunological actions of cyclosporin A in rheumatoid arthritis: D. Yocum; Br. J. Rheumatol. 32, 38 (1993)
The antimicrobial activities of cyclosporine, FK506, and rapamycin: H.P. High; Tansplantation 57, 1689 (1994) (Review)
Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2: A.R. Gottschalk, et al.; PNAS 91, 7350 (1994)
Inhibition of the mitochondrial permeability transition pore by cyclosporin A during long time frame experiments: relationship between pore opening and the activity of mitochondrial phospholipases. K.M. Broekemeier & D.R. Pfeiffer; Biochemistry 34, 16440 (1995)
Effects of cyclosporin A and FK506 on nitric oxide and tetrahydrobiopterin synthesis in bacterial lipopolysaccharide-treated J774 macrophages: Y. Hattori & N. Naranishi; Cell Immunol. 165, 7 (1995)
Inhibition of T lymphocyte activation and apoptotic cell death by cyclosporin A and tacrolimus (FK506). Its relevance to therapy of HIV infection: A.W. Thomson & C.A. Bonham; Adv. Exp. Med. Biol. 374, 211 (1995) (Review)
FK506 in the treatment of inflammatory skin disease: promises and perspectives: G. Michel, et al.; Immunol. Today 17, 106 (1996) (Review)
The antiparasite effects of cyclosporin A: possible drug targets and clinical applications: A. Bell, et al.; Gen. Pharmacol. 27, 963 (1996) (Review)
The mechanism of action of cyclosporin A and FK506: S. Ho, et al.; Clin. Immunol. Immunopathol. 80, S40 (1996) (Review)
Calcineurin phosphatase activity and immunosuppression. A review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporin A and tacrolimus: K.A. Jorgensen, et al.; Scand. J. Immunol. 57, 93 (2003) (Review)
Suppression of NF-kappaB by cyclosporin A and tacrolimus (FK506) via induction of the C/EBP family: implication for unfolded protein response: S. Du, et al.; J. Immunol. 182, 7201 (2009)
Melatonin suppresses cyclosporine A-induced autophagy in rat pituitary GH3 cells: Y.M. Yoo & E.B. Jeung; J. Pineal Res. 48, 204 (2010)
|Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.|